Conagen’s fermentation platform expands on promising novel forms of vitamin K2
Bedford, Mass., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Biotech innovator, Conagen announced the development of its fermentation-derived vitamin K2 - a high-purity all-trans menaquinone-7 (MK-7). This is the first molecule from a proprietary platform for producing novel, pure, long-chain menaquinone forms of the vitamin. The platform enables low-cost manufacturing and yields high-quality products, making it attractive to health brands. “Conagen’s...
Read more